CD79A and COVID-19: Non-criteria aPL, such as immunoglobulin (Ig) A anti-β2-glycoprotein I antibody (anti-β2GPI), which have promising clinical implications, have been proposed as additional indicators, especially in seronegative APS (SNAPS).[3] This report describes a CAPS patient with COVID-19 who presented with pain and swelling caused by multiple thrombi and multiple organ dysfunction, and was positive for IgA anti-β2GPI on testing.